Seeking Alpha

Seattle Genetics (SGEN -0.9%) announces that its cancer medicine Adcetris performed well when...

Seattle Genetics (SGEN -0.9%) announces that its cancer medicine Adcetris performed well when combined with more established treatments in a phase I trial on advanced stage Hodgkin lymphoma patients. The firm says it will now move forward with a phase III clinical trial based on the positive results.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs